Seoul Pharma Co., Ltd (KOSDAQ:018680)
South Korea · Delayed Price · Currency is KRW 1,956.00
0.00 (0.00%)
At close: Sep 11, 2026
Seoul Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 51,078 | 52,149 | 53,580 | 52,459 | 50,057 | 40,463 |
| 51,078 | 52,149 | 53,580 | 52,459 | 50,057 | 40,463 | |
Revenue Growth | -2.14% | -2.67% | 2.14% | 4.80% | 23.71% | -22.53% |
Cost of Revenue | 20,758 | 20,646 | 20,651 | 20,871 | 17,910 | 14,980 |
Gross Profit | 30,320 | 31,503 | 32,929 | 31,588 | 32,146 | 25,483 |
Selling, General & Admin | 27,533 | 29,216 | 27,973 | 26,710 | 27,154 | 24,805 |
Research & Development | 2,752 | 2,752 | 2,620 | 3,141 | 3,263 | 6,367 |
Amortization of Goodwill & Intangibles | 27.99 | 27.99 | 31.79 | 37.07 | - | - |
Operating Expenses | 31,100 | 32,782 | 31,401 | 30,375 | 30,408 | 31,197 |
Operating Income | -779.94 | -1,279 | 1,528 | 1,213 | 1,739 | -5,713 |
Interest Expense | -577.3 | -577.3 | -442.12 | -442.51 | -1,124 | -1,132 |
Interest & Investment Income | 229.41 | 229.41 | 301.9 | 383.64 | 325.22 | 122.1 |
Currency Exchange Gain (Loss) | 4.46 | 4.46 | 256.31 | 15.32 | 72.17 | 87.73 |
Other Non Operating Income (Expenses) | 2,795 | 2,256 | 49.15 | 2,819 | 45.18 | -2,760 |
EBT Excluding Unusual Items | 1,672 | 633.35 | 1,693 | 3,988 | 1,057 | -9,396 |
Gain (Loss) on Sale of Investments | - | - | 67.49 | 63.71 | - | - |
Gain (Loss) on Sale of Assets | -1.78 | -1.78 | -0.05 | -8.26 | -0.02 | 2.19 |
Asset Writedown | - | - | - | - | -2,177 | -198.8 |
Pretax Income | 1,670 | 631.57 | 1,760 | 4,044 | -1,120 | -9,592 |
Income Tax Expense | -68.69 | -122.07 | 61.86 | 526.39 | -1,975 | 96.14 |
Net Income | 1,739 | 753.64 | 1,699 | 3,517 | 855.09 | -9,689 |
Net Income to Common | 1,739 | 753.64 | 1,699 | 3,517 | 855.09 | -9,689 |
Net Income Growth | - | -55.63% | -51.71% | 311.34% | - | - |
Shares Outstanding (Basic) | - | 12 | 12 | 12 | 9 | 9 |
Shares Outstanding (Diluted) | - | 12 | 12 | 12 | 9 | 9 |
Shares Change | - | - | - | 29.84% | 5.34% | 0.31% |
EPS (Basic) | - | 64.64 | 145.69 | 301.68 | 95.23 | -1136.55 |
EPS (Diluted) | - | 64.64 | 145.69 | 301.68 | 95.23 | -1136.55 |
EPS Growth | - | -55.63% | -51.71% | 216.80% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 8,928 | 1,025 | -5,237 | 3,372 | -1,311 | -2,831 |
Free Cash Flow Per Share | - | 87.87 | -449.20 | 289.20 | -146.00 | -332.16 |
Gross Margin | 59.36% | 60.41% | 61.46% | 60.21% | 64.22% | 62.98% |
Operating Margin | -1.53% | -2.45% | 2.85% | 2.31% | 3.47% | -14.12% |
Profit Margin | 3.40% | 1.44% | 3.17% | 6.71% | 1.71% | -23.95% |
Free Cash Flow Margin | 17.48% | 1.97% | -9.78% | 6.43% | -2.62% | -7.00% |
EBITDA | 1,882 | 1,383 | 4,017 | 3,141 | 4,352 | -3,185 |
EBITDA Margin | 3.68% | 2.65% | 7.50% | 5.99% | 8.69% | -7.87% |
D&A For EBITDA | 2,662 | 2,662 | 2,490 | 1,928 | 2,613 | 2,528 |
EBIT | -779.94 | -1,279 | 1,528 | 1,213 | 1,739 | -5,713 |
EBIT Margin | -1.53% | -2.45% | 2.85% | 2.31% | 3.47% | -14.12% |
Effective Tax Rate | - | - | 3.51% | 13.02% | - | - |
Advertising Expenses | - | 90.06 | 244.7 | 282.26 | 340.07 | 306.66 |